Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more
Market Cap & Net Worth: Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (NASDAQ:DFTX) has a market capitalization of $1.83 Billion ($1.83 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5394 globally and #3189 in its home market, demonstrating a 3.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Definium Therapeutics, Inc.'s stock price $18.32 by its total outstanding shares 99698129 (99.70 Million).
Definium Therapeutics, Inc. Market Cap History: 2026 to 2026
Definium Therapeutics, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $1.83 Billion to $1.83 Billion (0.00% CAGR).
Definium Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Definium Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DFTX by Market Capitalization
Companies near Definium Therapeutics, Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Definium Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Definium Therapeutics, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Definium Therapeutics, Inc.'s market cap moved from $1.83 Billion to $ 1.83 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Definium Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.83 Billion USD |
| MoneyControl | $1.83 Billion USD |
| MarketWatch | $1.83 Billion USD |
| marketcap.company | $1.83 Billion USD |
| Reuters | $1.83 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.